Patents by Inventor Hans-Georg Lerchen

Hans-Georg Lerchen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190365916
    Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 5, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Sandra BERNDT, Lisa DIETZ, Stephan MÄRSCH, Stefanie HAMMER
  • Patent number: 10485880
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 26, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg Lerchen, Sven Wittrock, Yolanda Cancho Grande, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Christoph Mahlert, Anne-Sophie Rebstock, Carsten Terjung, Simone Greven
  • Publication number: 20190351066
    Abstract: The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which La, n, R and D have the definitions given in the description and which have a structural motif reduced to an asparagine derivative as cleavage site for tumour-associated proteases such as legumain, in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are released by legumain cleavage, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers. Reduction of the legumain-cleavable substrate peptide sequence to an asparagine derivative as structural motif, as a result of slowed legumain cleavage, achieves an increase in stability in the lysosomes of healthy organs while simultaneously maintaining the high anti-tumour effect.
    Type: Application
    Filed: December 18, 2017
    Publication date: November 21, 2019
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Leo MARX, Sarah Anna Liesa JOHANNES, Beatrix STELTE-LUDWIG, Lisa DIETZ, Hannah JOERISSEN, Christoph MAHLERT, Simone GREVEN, Anette SOMMER
  • Publication number: 20190328897
    Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 31, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
  • Publication number: 20190330357
    Abstract: The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 31, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH
  • Publication number: 20190262463
    Abstract: The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: August 29, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg LERCHEN, Yolanda CANCHO GRANDE, Beatrix STELTE-LUDWIG, Anette SOMMER, Christoph MAHLERT, Anne-Sophie REBSTOCK, Simone GREVEN, Nils GRIEBENOW, Jan TEBBE, Oliver KENSCH
  • Patent number: 10350206
    Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: July 16, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Anne Mengel, Hans-Georg Lerchen, Manfred Möwes, Thomas Müller, Lars Bärfacker, Marion Hitchcock, Arwed Cleve, Joachim Kuhnke, Hans Briem, Gerhard Siemeister, Wilhelm Bone, Amaury Ernesto Fernandez-Montalvan, Jens Schröder, Ursula Mönning, Simon Holton
  • Publication number: 20190077752
    Abstract: The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are masked with legumain-cleavable groups and hence release the drug, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers.
    Type: Application
    Filed: March 21, 2017
    Publication date: March 14, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Leo MARX, Sarah Anna Liesa JOHANNES, Beatrix STELTE-LUDWIG, Lisa DIETZ, Carsten TERJUNG, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT
  • Publication number: 20180318438
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: November 8, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Stephan MÄRSCH, Uwe GRITZAN, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT, Lisa DIETZ
  • Publication number: 20180318437
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: November 8, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO-GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Dennis KIRCHHOFF
  • Patent number: 10035818
    Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: July 31, 2018
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbH
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Köllnberger, Frank Wunder, Gorden Redlich, Andreas Knorr, Julie Marley, Iain Pritchard
  • Patent number: 10022453
    Abstract: The present application relates to novel antibody drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 17, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Sven Wittrock, Nils Griebenow, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Christoph Mahlert, Mario Lobell, Carsten Terjung, Simone Greven, Yolanda Cancho Grande
  • Publication number: 20180185510
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: July 5, 2018
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Uwe GRITZAN, Pedro PAZ, Melanie FISCHER, Juergen FRANZ, Julian Marius GLÜCK, Stephan MÄRSCH, Beatrix STELTE-LUDWIG, Christoph MAHLERT, Ernst WEBER, Simone GREVEN, Sandra BERNDT
  • Publication number: 20180169256
    Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.
    Type: Application
    Filed: June 20, 2016
    Publication date: June 21, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Leo MARX, Beatrix STELTE-LUDWIG, Carsten TERJUNG, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT
  • Publication number: 20180015176
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: December 10, 2015
    Publication date: January 18, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Sven WITTROCK, Yolanda CANCHO GRANDE, Beatrix STELTE-LUDWIG, Anette SOMMER, Sandra BERNDT, Christoph MAHLERT, Anne-Sophie REBSTOCK, Carsten TERJUNG, Simone GREVEN
  • Publication number: 20170342064
    Abstract: The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, and their use for the treatment and/or prophylaxis of diseases.
    Type: Application
    Filed: December 7, 2015
    Publication date: November 30, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Volker SCHULZE, Hans-Georg LERCHEN, Ulrich LÜCKING, Antje Margret WENGNER, Gerhard SIEMEISTER, Philip LIENAU, Ursula KRENZ
  • Publication number: 20170305882
    Abstract: Compounds of formula (I) and their use as pharmaceuticals.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 26, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Anne MENGEL, Hans-Georg LERCHEN, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNÁNDEZ-MONTÁLVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
  • Publication number: 20170273980
    Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.
    Type: Application
    Filed: September 17, 2015
    Publication date: September 28, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Anne MENGEL, Hans-Georg LERCHEN, Manfred MÖWES, Thomas MÜLLER, Lars BÄRFACKER, Marion HITCHCOCK, Arwed CLEVE, Joachim KUHNKE, Hans BRIEM, Gerhard SIEMEISTER, Wilhelm BONE, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Ursula MÖNNING, Simon HOLTON
  • Publication number: 20170204137
    Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 20, 2017
    Inventors: Ingo FLAMME, Johannes KÖBBERLING, Hans-Georg LERCHEN, Nils GRIEBENOW, Rudolf SCHOHE-LOOP, Sven WITTROCK, Maria KÖLLNBERGER, Frank WUNDER, Gorden REDLICH, Andreas KNORR, Julie MARLEY, Iain PRITCHARD
  • Patent number: 9649363
    Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: May 16, 2017
    Assignees: BAYER INTELLECTUAL PROPERTY GMBH, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Köllnberger, Frank Wunder, Gorden Redlich, Andreas Knorr, Julie Marley, Iain Pritchard